(Q83523415)
Statements
FACT: an open-label randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer (English)
Jonas Bergh
Per-Ebbe Jönsson
Elisabet Kerstin Lidbrink
Maureen Trudeau
Wolfgang Eiermann
Daniel Brattström
Fredrik Wiklund
Roger Henriksson
27 February 2012